Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077233 · ClinicalTrials.gov registry record · Phase 3
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
NCT00077233 is a Phase 3 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 238 participants.
The verdict
NCT00077233, a Phase 3 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
Study Summary
This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon cancer regardless of tumor status with respect to EGFR.
Interventions
- DRUG cetuximab
- DRUG 5-FU
- DRUG oxaliplatin
- DRUG leucovorin
- DRUG irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2003-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077233
The ClinicalTrials.gov registry entry for NCT00077233 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cetuximab is the first listed.
NCT00077233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077233 about?
NCT00077233 is a clinical study titled "FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum". This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon cancer regardless of tumor status with respect to EGFR.
What is the current status of trial NCT00077233?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2003-12. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00077233?
The interventions under investigation include: cetuximab (DRUG), 5-FU (DRUG), oxaliplatin (DRUG), leucovorin (DRUG), irinotecan (DRUG).
Who is sponsoring clinical trial NCT00077233?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.